Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a phase I, open label, dose escalation study to evaluate tolerability, safety ,
pharmacokinetics and efficacy in patients with KRAS mutant NSCLC by using HL-085 and
Docetaxel.